| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.400 | 5.971 | 8.340 | 9.058 | 12.349 | 14.412 | 13.979 | 23.502 | 5.073 | 0 |
| Total Income - EUR | 7.418 | 5.971 | 8.726 | 9.362 | 12.349 | 14.412 | 14.953 | 23.530 | 5.073 | 0 |
| Total Expenses - EUR | 4.534 | 4.711 | 7.013 | 6.379 | 8.901 | 8.857 | 6.900 | 19.051 | 7.673 | 143 |
| Gross Profit/Loss - EUR | 2.884 | 1.261 | 1.713 | 2.983 | 3.448 | 5.555 | 8.053 | 4.479 | -2.600 | -143 |
| Net Profit/Loss - EUR | 2.662 | 1.082 | 1.447 | 2.702 | 3.078 | 5.122 | 7.614 | 3.773 | -2.650 | -143 |
| Employees | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Bioquant 3D Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 4.494 | 3.073 | 2.097 | 1.479 | 652 | 220 | 63 | 0 | 0 | 0 |
| Current Assets | 32.047 | 31.465 | 32.331 | 33.377 | 34.746 | 38.654 | 41.974 | 45.951 | 40.897 | 40.540 |
| Inventories | 157 | 0 | 44 | 117 | 54 | 136 | 464 | 996 | 993 | 906 |
| Receivables | 30.547 | 31.217 | 30.697 | 31.309 | 34.370 | 32.900 | 38.349 | 40.801 | 36.731 | 36.525 |
| Cash | 1.343 | 247 | 1.590 | 1.951 | 323 | 5.618 | 3.161 | 4.154 | 3.173 | 3.109 |
| Shareholders Funds | 35.757 | 33.839 | 33.651 | 34.317 | 34.623 | 36.463 | 39.225 | 39.064 | 33.162 | 32.834 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 784 | 698 | 777 | 539 | 776 | 2.411 | 2.812 | 6.887 | 7.736 | 7.707 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
7111
|
|||||||||
Comments - Bioquant 3D Srl